Pros | ![]() Beats FD returns for both 3Y & 5Y duration. | |||
Cons | - |
INDMoney rank | 6/8 | |||
Category,Subcateogry | Equity,Sector - Healthcare | |||
Fund Age | 12 Years | |||
Fund Size | 1057 Cr | |||
Min Investment | SIP ₹500 Lumpsum ₹5000 | |||
Expense Ratio | 1.23% | |||
Exit Load | 1% | |||
Benchmark Index | S&P BSE Healthcare PR |
No of Holdings | 45 | |||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (10.93%) Cipla Ltd (6.19%) Dr Reddy's Laboratories Ltd (4.57%) Ajanta Pharma Ltd (4.43%) Glenmark Pharmaceuticals Ltd (3.74%) | |||
No of Sectors | 2 | |||
Top 3 Sectors | Health (98.66%) Basic Materials (1.34%) | |||
Equity % | 99.55% | |||
Debt % | - | |||
P/E | 34.67 | |||
P/B | 5.43 | |||
Credit Quality | - | |||
Modified Duration | - | |||
YTM | - |
1-Month Return | 6.66% | |||
3-Month Return | -9.76% | |||
6-Month Return | -8.63% | |||
1-Year Return | 18.18% | |||
3-Year Return | 20.13% | |||
5-Year Return | 28.62% |
Sharpe | 0.84 | |||
Alpha | 1.26 | |||
Beta | 0.96 | |||
Standard Deviation | 16.7 | |||
Information Ratio | 0.31 |
Description | UTI Healthcare Fund-Growth Option- Direct is an equity fund.The fund could potentially beat inflation in the long-run. | |||
Managers | - |